Every 10-Q that Neuphoria Therapeutics Inc. (NEUP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NEUP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NEUP filings page.
Neuphoria Therapeutics Inc. reported a small net loss of $0.5 million for the three months ended March 31, 2026, compared with net income of $11.3 million a year earlier, when it booked a large Merck milestone payment. There was no revenue this quarter.
Following the failure of its AFFIRM‑1 phase 3 trial in social anxiety disorder, the company has discontinued the BNC210 SAD program, paused the BNC210 PTSD program, terminated virtually all employees and exited its main facility, recording $1.3 million of restructuring costs over nine months.
Neuphoria raised $17.9 million net through equity sales, ending the period with cash and cash equivalents of $19.4 million and working capital of about $20.1 million. Management expects this to fund operations beyond the fourth quarter of fiscal 2027 and sees no substantial doubt about continuing as a going concern while it pursues strategic alternatives.
Neuphoria Therapeutics Inc. reported net income of $1.9 million for the quarter ended December 31 2025, driven largely by a $5.4 million gain on fair value adjustments to warrant and contingent consideration liabilities. This contrasts with a net loss of $1.9 million a year earlier.
For the six months ended December 31 2025, the company recorded a net loss of $8.0 million. Cash, cash equivalents and restricted cash rose to $22.3 million, supported by $17.9 million in equity financing, and management believes this will fund operations beyond the third quarter of fiscal 2027.
After a Phase 3 trial of BNC210 in social anxiety disorder failed its primary endpoint, Neuphoria discontinued that program, paused its PTSD program, terminated nearly all employees and exited its main facility, booking $1.2 million in restructuring costs. The company adopted a shareholder rights plan and is pursuing strategic alternatives, including potential mergers, acquisitions or other transactions, while maintaining partnerships such as its Merck collaboration.
Neuphoria Therapeutics (NEUP) reported Q1 FY2026 results for the quarter ended September 30, 2025. Operating expenses were $5.65 million, driven mainly by R&D on BNC210. The company posted a net loss of $9.91 million and basic/diluted loss per share of $4.41. Other loss reflected a $4.37 million non‑cash decrease from fair value adjustments.
Cash and cash equivalents were $13.65 million, with total assets of $27.34 million and shareholders’ equity of $12.51 million. Subsequent to quarter end, the company raised approximately $15.1 million via its ATM, which management says supports operations beyond the second quarter of fiscal 2027. As of November 13, 2025, common shares outstanding were 5,377,329.
After quarter end, the AFFIRM‑1 Phase 3 trial in social anxiety disorder did not meet its primary endpoint, and the SAD program will be discontinued. The company plans to evaluate next steps for BNC210 in PTSD, initiated a strategic review, and adopted a limited-duration shareholder rights plan expiring October 27, 2026.